[go: up one dir, main page]

WO1995005851A1 - Compositions relatives au facteur viral infectieux de hiv, utilisations prophylactiques et therapeutiques - Google Patents

Compositions relatives au facteur viral infectieux de hiv, utilisations prophylactiques et therapeutiques Download PDF

Info

Publication number
WO1995005851A1
WO1995005851A1 PCT/US1994/009313 US9409313W WO9505851A1 WO 1995005851 A1 WO1995005851 A1 WO 1995005851A1 US 9409313 W US9409313 W US 9409313W WO 9505851 A1 WO9505851 A1 WO 9505851A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
infected
vif
subject
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/009313
Other languages
English (en)
Inventor
David J. Volsky
Mary Jane Potash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Lukes Roosevelt Hospital Center
Original Assignee
St Lukes Roosevelt Hospital Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Lukes Roosevelt Hospital Center filed Critical St Lukes Roosevelt Hospital Center
Priority to AU75687/94A priority Critical patent/AU7568794A/en
Publication of WO1995005851A1 publication Critical patent/WO1995005851A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the subject invention further provides a composition which comprises an effective amount of a recombinant non- HIV virus capable of infecting a suitable host cell, said recombinant virus comprising a nucleic acid molecule (a) encoding an anti-sense oligonucleotide molecule capable of specifically binding to an mRNA molecule encoding HIV vif protein, at the portion thereof encoding the HIV vif protein, so as to prevent translation of the mRNA molecule, and (b) capable of being expressed in the suitable host cell, and a pharmaceutically acceptable carrier.
  • a nucleic acid molecule (a) encoding an anti-sense oligonucleotide molecule capable of specifically binding to an mRNA molecule encoding HIV vif protein, at the portion thereof encoding the HIV vif protein, so as to prevent translation of the mRNA molecule, and (b) capable of being expressed in the suitable host cell, and a pharmaceutically acceptable carrier.
  • nucleic acid molecule includes DNA and RNA.
  • the nucleic acid molecule is a DNA molecule.
  • DNA includes, for example, cDNA and genomic DNA.
  • the DNA molecule may be a plasmid.
  • the nucleic acid molecule is an RNA molecule.
  • Obtaining a sample of hematopoietic stem cells may be accomplished according to methods well known to those skilled in the art. Such methods include, for example, taking a needle sample of bone marrow from a subject. Culturing hematopoietic stem cells may also be accomplished according to methods well known to those skilled in the art.
  • HIV-l vif-negative human immunodeficiency virus type 1
  • poly erase chain reaction amplification, cloning, and sequencing to investigate the vif region of replicating virus in short term pas ⁇ age HIV-l primary i ⁇ olates from five asymptomatic individual ⁇ and from five person ⁇ with AIDS.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un vaccin comprenant vif-VIH, une molécule d'acide nucléique codant vif-VIH, une molécule d'acide nucléique codant un oligonucléotide antisens de vif et une molécule d'acide nucléique codant une protéine mutante non fonctionnelle de Vif pouvant inhiber la fonction de Vif de type sauvage. L'invention s'utilisera pour limiter la susceptibilité d'un individu à une infection par VIH et pour traiter un malade infecté par VIH.
PCT/US1994/009313 1993-08-20 1994-08-19 Compositions relatives au facteur viral infectieux de hiv, utilisations prophylactiques et therapeutiques Ceased WO1995005851A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75687/94A AU7568794A (en) 1993-08-20 1994-08-19 Hiv (vif)-related compositions, and prophylactic and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11022693A 1993-08-20 1993-08-20
US08/110,226 1993-08-20

Publications (1)

Publication Number Publication Date
WO1995005851A1 true WO1995005851A1 (fr) 1995-03-02

Family

ID=22331893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009313 Ceased WO1995005851A1 (fr) 1993-08-20 1994-08-19 Compositions relatives au facteur viral infectieux de hiv, utilisations prophylactiques et therapeutiques

Country Status (2)

Country Link
AU (1) AU7568794A (fr)
WO (1) WO1995005851A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015009A4 (fr) * 1997-09-18 2001-11-07 Univ Pennsylvania Materiau genetique sous forme de cassettes d'immunisation a base d'adn de vif attenue pour des vaccins genetiques
WO2002026253A1 (fr) * 2000-08-18 2002-04-04 Tsinghua University Vaccin contre le sida, son procede de preparation et ses applications
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US7220554B2 (en) 2003-05-23 2007-05-22 Oregon Health And Science University Methods for identifying inhibitors
US7226741B2 (en) 2001-04-06 2007-06-05 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target
US8008469B2 (en) 2003-10-23 2011-08-30 Avi Biopharma Inc. Antisense compound for inducing immunological tolerance
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US8592386B2 (en) 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (fr) * 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
FR2647809A1 (fr) * 1989-06-02 1990-12-07 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
EP0403333A2 (fr) * 1989-06-02 1990-12-19 Institut Pasteur Séquences nucléotidiques issues du génome des rétrovirus du typ hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des génomes de ces rétrovirus et pour le diagnostic in-vitro des infections dues à ces virus
WO1991005864A1 (fr) * 1989-10-13 1991-05-02 Connaught Laboratories Limited Production par genie genetique de vaccin contre le sida et contre les maladies retrovirales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (fr) * 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
FR2647809A1 (fr) * 1989-06-02 1990-12-07 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
EP0403333A2 (fr) * 1989-06-02 1990-12-19 Institut Pasteur Séquences nucléotidiques issues du génome des rétrovirus du typ hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des génomes de ces rétrovirus et pour le diagnostic in-vitro des infections dues à ces virus
WO1991005864A1 (fr) * 1989-10-13 1991-05-02 Connaught Laboratories Limited Production par genie genetique de vaccin contre le sida et contre les maladies retrovirales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AIDS RESEARCH AND HUMAN RETROVIRUSES, Volume 8, Number 3, issued March 1992, R.C. DESROSIERS, "HIV With Multiple Gene Deletions as a Live Attenuated Vaccine for AIDS", pages 411-421. *
NUCLEIC ACIDS RESEARCH, Volume 19, Number 7, issued 1991, K. RITTNER et al., "Identification and Analysis of Antisense RNA Target Regions of the Human Immunodeficiency Virus Type I", pages 1421-1426. *
PROC. NATL. ACAD. SCI. U.S.A., Volume 90, issued February 1993, P.F. TORRENCE et al., "Targeting RNA For Degradation With a (2'-5')Oligoadenylate-Antisense Chimera", pages 1300-1304. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
EP1015009A4 (fr) * 1997-09-18 2001-11-07 Univ Pennsylvania Materiau genetique sous forme de cassettes d'immunisation a base d'adn de vif attenue pour des vaccins genetiques
US7151172B1 (en) 1997-09-18 2006-12-19 The Trustees Of The University Of Pennsylvania Attenuated vif DNA immunization cassettes for genetic vaccines
EP2044950A3 (fr) * 1997-09-18 2009-07-01 The Trustees Of The University Of Pennsylvania Cassettes d'immunisation ADN VIF atténuée pour vaccins génétiques
US8183352B2 (en) 1997-09-18 2012-05-22 The Trustees Of The University Of Pennsylvania Attenuated vif DNA immunization cassettes for genetic vaccines
WO2002026253A1 (fr) * 2000-08-18 2002-04-04 Tsinghua University Vaccin contre le sida, son procede de preparation et ses applications
US7226741B2 (en) 2001-04-06 2007-06-05 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target
US7498138B2 (en) 2001-04-06 2009-03-03 Thomas Jefferson University Multimerization of HIV-1 Vif protein as a therapeutic target
US7220554B2 (en) 2003-05-23 2007-05-22 Oregon Health And Science University Methods for identifying inhibitors
US8008469B2 (en) 2003-10-23 2011-08-30 Avi Biopharma Inc. Antisense compound for inducing immunological tolerance
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US8592386B2 (en) 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis

Also Published As

Publication number Publication date
AU7568794A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
Sova et al. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1
Tagaya et al. 40 years of the human T-cell leukemia virus: past, present, and future
Kowalski et al. Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein
Courcoul et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif-human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps
Sodroski et al. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions
Chesebro et al. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes
Simon et al. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes
Li et al. Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation
von Schwedler et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells
Bou-Habib et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
Connor et al. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
Simm et al. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes
Ottmann et al. The central globular domain of the nucleocapsid protein of human immunodeficiency virus type 1 is critical for virion structure and infectivity
Shibata et al. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo
AGY et al. Interferon treatment inhibits virus replication in HIV-1-and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins
Kirchhoff et al. The" V3" domain is a determinant of simian immunodeficiency virus cell tropism
MICHAELS et al. The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2
Mikovits et al. In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus
Mammano et al. Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1
WO1995005851A1 (fr) Compositions relatives au facteur viral infectieux de hiv, utilisations prophylactiques et therapeutiques
JPH05501654A (ja) 霊長類レンチウイルスワクチン
Volsky et al. Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4
Agy et al. Serialin VivoPassage of HIV-1 Infection inMacaca nemestrina
Bernier et al. Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1
Reddy et al. Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA